BioXcel Therapeutics (BTAI) Change in Accured Expenses (2017 - 2026)

BioXcel Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 197.62% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $4.5 million (up 287.93% YoY), while the FY2024 annual figure was -$736000.0, up 77.14% from the prior year.
• Change in Accured Expenses was $2.2 million for Q1 2026 at BioXcel Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.2 million in Q4 2022 to a low of -$4.7 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $752666.7 across 5 years, with a median of $261000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 2458.33% in 2022, then tumbled 588.46% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $9.2 million in 2022, then plunged by 147.34% to -$4.4 million in 2023, then jumped by 105.97% to $261000.0 in 2024, then surged by 769.35% to $2.3 million in 2025, then slipped by 2.38% to $2.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.2 million (Q1 2026), $2.3 million (Q2 2025), and -$2.3 million (Q1 2025), per Business Quant data.